跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 5,010 条关于
“IBIO-610”
全部
5,010
临床试验
2,002
药物
1,575
机构
203
资讯
1,230
6个月前
iBio's IBIO-610 Shows Fat-Selective Weight Loss in Non-Human Primate Study
10个月前
iBio's IBIO-610 Activin E Antibody Shows 100-Day Human Half-Life Potential for Twice-Yearly Obesity Treatment
11个月前
iBio to Present Preclinical Data on First-in-Class Activin E Antibody IBIO-610 for Obesity Treatment
6个月前
iBio Advances Bispecific Antibody for Pulmonary Hypertension in Heart Failure, Targets Q3 2026 Development Candidate
去年
iBio Advances AI-Driven Obesity Pipeline with Myostatin and Activin E Antibody Therapies
去年
iBio Licenses First-in-Class Antibody Targeting Activin E for Obesity and Cardiometabolic Diseases
去年
Sol-Gel Technologies Advances SGT-610 for Gorlin Syndrome and SGT-210 for Darier Disease
去年
Sol-Gel Completes Phase 3 Enrollment for Gorlin Syndrome Treatment SGT-610, Targets $300M Peak Revenue
3个月前
AI-Powered Cellular Reprogramming Attracts Major Investment as Biotech Firms Target US$610 Billion Longevity Market
9个月前
Sol-Gel Discontinues SGT-210 Development for Darier Disease After Phase 1b Trial Fails to Show Efficacy
第 1 页,共 123 页
上一页
下一页